Antiepileptic drugs in the treatment of psychiatric disorders

Epilepsy and Behavior

Volumn 21, Issue 1, 2011, Pages 1-11

  Kaufman, Kenneth R ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Adverse effects; Affective disorders; Antiepileptic drugs; Anxiety disorders; Epilepsy; FDA and European Medicines Agency indications; Impulse control disorders; Psychiatric disorders; Psychotic disorders; Psychotropic properties; Substance abuse; Treatment

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ESLICARBAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RETIGABINE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

BIPOLAR DISORDER; COMORBIDITY; DRUG APPROVAL; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL DISEASE; OFF LABEL DRUG USE; PAIN; REVIEW; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; TREATMENT INDICATION;

ANTICONVULSANTS; HUMANS; MENTAL DISORDERS;

EID: 79955627092     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.03.011     Document Type: Review

References (270)

1. Kaufman K.R., Kugler S.L., Sachdeo R.C. Tiagabine in the management of post-encephalitic epilepsy and impulse control disorder. Epilepsy Behav 2002, 3:190-194.
2. Ketter T.A., Wang P.W., Becker O.V., Nowakowska C., Yang Y.S. The diverse roles of anticonvulsants in bipolar disorder. Ann Clin Psychiatry 2003, 15:95-108.
3. Landmark C.J. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008, 22:27-47.
4. Sussman N., Ettinger A.B. Psychotropic properties of antiepileptic drugs. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment 2007, 67-82. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. A.B. Ettinger, A.M. Kanner (Eds.).
5. Eisenberg E., River Y., Shifrin A., Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007, 67:1265-1289.
6. Savica R., Beghi E., Mazzaglia G., et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol 2007, 14:1317-1321.
7. Garcia-Morales I., de la Pena Mayor P., Kanner A.M. Psychiatric comorbidities in epilepsy: identification and treatment. Neurologist 2008, 14(6, Suppl. 1):S15-S25.
8. McElroy S.L., Keck P.E., Post R.M. Antiepileptic drugs to treat psychiatric disorders 2007, Informa Health Care, New York.
9. Shneker B.F., Cios J.S., Elliott J.O. Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert. Neurology 2009, 72:987-991.
10. Mula M., Sander J.W. Mood. Behavioral aspects of epilepsy: principles and practice 2008, 289-294. Demos Medical, New York. S.C. Schachter, G.L. Holmes, D.G. Trenite (Eds.).
11. Ovsiew F. Antiepileptic drugs in psychiatry. J Neurol Neurosurg Psychiatry 2004, 75:1655-1658.
12. Kaufman K.R. Monotherapy treatment of bipolar disorder with levetiracetam. Epilepsy Behav 2004, 5:1017-1020.
13. Goodnick P.J. Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother 2006, 7:401-410.
14. Considering the evidence: antiepileptic medications for bipolar disorder. J Psychiatr Pract 2008, 14(Suppl. 1):7-56.
15. Steinman M.A., Bero L.A., Chren M., Landefeld C.S. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006, 145:284-293.
16. Fullerton C.A., Busch A.B., Frank R.G. The rise and fall of gabapentin for bipolar disorder: a case on off-label pharmaceutical diffusion. Med Care 2010, 48:372-379.
17. Chen H., Deshpande A.D., Jiang R., Martin B.C. An epidemiological investigation of off-label anticonvulsant use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf 2005, 14:629-638.
18. Zito J.M., Safer D.J., Gardner J.F., Soeken K., Ryu J. Anticonvulsant treatment for psychiatric and seizure indications among youths. Psychiatr Ser 2006, 57:681-685.
19. Barry J.J., Ettinger A.B., Friel P., et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorder. Epilepsy Behav 2008, 13:S1-S29.
20. Jones J.E., Hermann B.P., Barry J.J., Gilliam F., Kanner A.M., Meador K.J. Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci 2005, 17:172-179.
21. Kanner A.M. Mood disorders in epilepsy: two different disorders with common pathogenic mechanisms?. Behavioral aspects of epilepsy: principles and practice 2008, 195-208. Demos Medical, New York. S.C. Schachter, G.L. Holmes, D.G. Trenite (Eds.).
22. Kanner A.M., Palac S. Neuropsychiatric complications of epilepsy. Curr Neurol Neurosci Rep 2002, 2:365-372.
23. Perini G.I., Tosin C., Carraro C., et al. Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 1996, 61:601-605.
24. Moffitt T.E., Caspi A., Taylor A., et al. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol Med 2010, 40:899-909.
25. Christensen J., Vestergaard M., Mortensen P.B., Sidenius P., Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007, 6:693-698.
26. Andersohn F., Schade R., Willich S.N., Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010, 75:335-340.
27. Arana A., Wentworth C.E., Ayuso-Mateos J.L., Arellano F.M. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010, 363:542-551.
28. Gibbons R.D., Hur K., Brown C.H., Mann J.J. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009, 66:1354-1360.
29. Kaufman K.R., Struck P.J. Psychogenic nonepileptic seizures, epilepsy, and suicidal behavior on a video/EEG telemetry unit: the need for psychiatric assessment and screening for suicide risk. Epilepsy Behav 2010, 19:656-659.
30. Kaufman K.R., Struck P.J. Activation of suicidal ideation with rufinamide in bipolar disorder. Epilepsy Behav 2011, 20:386-389.
31. Mentari E.K., Stone M., Hammad T.A. Antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2010, 67:972.
32. Olesen J.B., Hansen P.R., Erdal J., et al. Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol Drug Saf 2010, 19:518-524.
33. Patorno E., Bohn R.L., Wahl P.M., et al. Anticonvulsant medications and the risk of suicide, attempted suicide or violent death. JAMA 2010, 303:1401-1409.
34. U.S.Food and Drug Administration Antiepileptic drugs and suicidality Available at:, Accessed on: 21 October 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM192556.
35. VanCott A.C., Cramer J.A., Copeland L.A., et al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med 2010, 8:4.
36. De Boer H.M., Mula M., Sander J.W. The global burden and stigma of epilepsy. Epilepsy Behav 2008, 12:540-546.
37. Coleman R., Loppy L., Walraven G. The treatment gap and primary health care for people with epilepsy in rural Gambia. Bull WHO 2002, 80:378-383.
38. Grabowska-Grzyb A., Jedrzejczak J., Naganska E., Fiszer U. Risk factors for depression in patients with epilepsy. Epilepsy Behav 2006, 8:411-417.
39. Mac T.L., Tran D.S., Quet F., Odermatt P., Preux P.M., Tan C.T. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol 2007, 6:533-543.
40. Nubukpo P., Preux P.M., Houinato D., et al. Psychosocial issues in people with epilepsy in Togo and Benin (West Africa): I. Anxiety and depression measured using Goldberg's scale. Epilepsy Behav 2004, 5:722-727.
41. Scott R.A., Lhatoo S.M., Sander J.W. The treatment of epilepsy in developing countries: where do we go from here?. Bull WHO 2001, 79:344-351.
42. Swinkels W.A., Kuyk J., van Dyck R., Spinhoven P. Psychiatric comorbidity in epilepsy. Epilepsy Behav 2005, 7:37-50.
43. Tellez-Zenteno J.F., Patten S.B., Jette N., Williams J., Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-2344.
44. Meador K.J. Cognitive effects of antiepileptic drugs. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment 2007, 83-92. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. A.B. Ettinger, A.M. Kanner (Eds.).
45. Baulac M., Cramer J.A., Mattson R.H. Adverse effects of phenobarbital and other barbiturates. Antiepileptic drugs 2002, 528-540. Lippincott Williams & Wilkins, Philadelphia. 5th ed. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
46. Lopez-Munoz F., Ucha-Udabe R., Alamo C. The history of barbiturates a century after introduction. Neurpsychiatr Dis Treat 1995, 1:329-343.
47. Wesson D.R., Smith D.E., Ling W., Seymour R.B. Sedative-hypnotics. Substance abuse: a comprehensive textbook 2004, 302-313. Lippincott Williams & Wilkins, Philadelphia. 4th ed. J.H. Lowinson, P. Ruiz, R.B. Millman, J.G. Langrod (Eds.).
48. Gold J.A., Rimal B., Nolan A., Nelson L.S. A strategy of escalating doses of benzodiazepine and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med 2007, 35:727-730.
49. Prater C.D., Miller K.E., Zylstra R.G. Outpatient detoxification of the addicted or alcoholic patient. Am Fam Physician 1999, 60:1175-1183.
50. Hayes S.G. Barbiturate anticonvulsants in refractory affective disorders. Ann Clin Psychiatry 1993, 5:35-44.
51. Schaffer L.C., Schaffer C.B., Caretto J. The use of primidone in the treatment of refractory bipolar disorder. Ann Clin Psychiatry 1999, 11:61-66.
52. Bobruff A., Gardos G., Tarsy D., Rapkin R.M., Cole J.O., Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 1981, 138:189-193.
53. Mishory Y., Yaroslavsky Y., Bersudsky Y., Belmaker R.H. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000, 157:463-465.
54. Bersudsky Y. Phenytoin: an anti-bipolar anticonvulsant?. Int J Neuropsychopharmacol 2006, 9:479-484.
55. Mula M., Pini S., Cassano G.B. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007, 27:263-272.
56. Barratt E.S., Stanford M.S., Felthous A.R., Kent T.A. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997, 17:341-349.
57. Stanford M.S., Helfritz L.E., Conklin S.M., et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 2005, 13:72-77.
58. Glauser T.A., Morita D.A. Ethosuximide. The treatment of epilepsy: Principles and practice 2005, 817-827. Lippincott Williams & Wilkins, Philadelphia. 4th edn. E. Wyllie, A. Gupta, D.K. Lachhwani (Eds.).
59. Walden J., Langosch J., Born C., Schaub G., Grunze H. Levetiracetam and ethosuximide in the treatment of acute mania in an open study with an on-off-on design. Bipolar Disord 2002, 4(Suppl. 1):114.
60. Raj A., Sheehan D. Benzodiazepines. The American Psychiatric Publishing textbook of psychopharmacology 2004, 371-389. American Psychiatric, Arlington. 3rd edn. A.F. Schatzberg, C.B. Nemeroff (Eds.).
61. Hosak L., Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry 2002, 17:371-378.
62. Saias T., Gallarda T. Paradoxical aggressive reactions to benzodiazepine use: a review. Encephale 2008, 34:330-336.
63. O'Brien C.P. Benzodiazepines use, abuse, and dependence. J Clin Psychiatry 2005, 66(Suppl. 2):28-33.
64. Chang G., Kosten T.R. Detoxification. Substance abuse: a comprehensive textbook 2004, 579-587. Lippincott Williams & Wilkins, Philadelphia. 4th ed. J.H. Lowinson, P. Ruiz, R.B. Millman, J.G. Langrod (Eds.).
65. Neubauer D.N. The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med 2007, 3(5, Suppl.):S11-S16.
66. Curtin F., Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord 2004, 78:201-208.
67. Fink M., Taylor M.A. Catatonia: a clinician's guide to diagnosis and treatment 2003, Cambridge Univ. Press, Cambridge.
68. Rappa L.R., Larose-Pierre M., Payne D.R., Eraikhuemen N.E., Lanes D.M., Kearson M.L. Detoxification from high-dose zolpidem using diazepam. Ann Pharmacother 2004, 38:590-594.
69. Jana A.K., Arora M., Khess C.R., Praharaj S.K. A case of zolpidem dependence successfully detoxified with clonazepam. Am J Addict 2008, 17:343-344.
70. Rowe T.O. Acetazolamide delirium. Am J Psychiatry 1977, 134:587-588.
71. Hayes S.G. Acetazolamide in bipolar affective disorders. Ann Clin Psychiatry 1994, 6:91-98.
72. Brandt C., Grunze H., Norman C., Walden J. Acetazolamide in the treatment of acute mania: a case report. Neuropsychobiology 1998, 38:202-203.
73. Inoue H., Hazama H., Hamazoe K., et al. Antipsychotic and prophylactic effects of acetazolamide (Diamox) on atypical psychosis. Folia Psychiatr Neurol Jpn 1984, 38:425-436.
74. Schneiderhan M.E., Marvin R. Is acetazolamide similar to topiramate for reversal of anti-psychotic weight gain?. Am J Ther 2007, 14:581-584.
75. Cowen M.A., Green M., Bertollo D.N., David N., Abbott K. A treatment for tardive dyskinesia and some other extrapyramidal symptoms. J Clin Psychopharmacol 1997, 17:190-193.
76. Arif H., Buchsbaum R., Weintraub D., Pierro J., Resor S.R., Hirsch L.J. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav 2009, 14:202-209.
77. Post R.M., Ketter T.A., Uhde T., Ballenger J.C. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 2007, 21:47-71.
78. Uhde T.W., Stein M.B., Post R.M. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988, 145:1104-1109.
79. Barrons R., Roberts N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther 2010, 35:153-167.
80. Pages K.P., Ries R.K. Use of anticonvulsants in benzodiazepine withdrawal. Am J Addict 1998, 7:198-204.
81. Garcia-Borreguero D., Bronisch T., Apelt S., Yassouridis A., Emrich H.M. Treatment of benzodiazepine withdrawal symptoms with carbamazepine. Eur Arch Psychiatry Clin Neurosci 1991, 241:145-150.
82. Schweizer E., Rickels K., Case W.G., Greenblatt D.J. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991, 48:448-452.
83. Black D.W., Shaw M.C., Allen J. Extended release carbamazepine in the treatment of pathological gambling: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1191-1194.
84. Nagata T., Harada D., Aoki K., et al. Effectiveness of carbamazepine for benzodiazepine-resistant impulsive aggression in a patient with frontal infarctions. Psychiatry Clin Neurosci 2007, 61:695-697.
85. Kritzinger P.R., Jordaan G.P. Catatonia: an open prospective series with carbamazepine. Int J Neuropsychopharmacol 2001, 4:251-257.
86. Bellino S., Paradiso E., Bogetto F. Pharmacotherapy of borderline personality disorder. CNS Drugs 2008, 22:671-692.
87. Leucht S., McGrath J., White P., Kissing W. Carbamazepine augmentation for schizophrenia: how good is the evidence?. J Clin Psychiatry 2002, 63:218-224.
88. Herrmann N., Lanctot K.L. Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 2007, 52:630-646.
89. Pinheiro D. Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD). Encephale 2008, 34:409-415.
90. Meador K.J., Baker G.A., Browning N., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
91. Sachs G.S., Gardner-Schuster E.E. Adjunctive treatment of acute mania: a clinical review. Acta Pschiatr Scand 2007, 116(Suppl. 434):27-34.
92. Ghaemi S.N., Gilmer W.S., Goldberg J.F., et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007, 68:1840-1844.
93. McElroy S.L., Bowden C.L., Collins M.A., Wozniak P.J., Keck P.E., Calabrese J.R. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. J Affect Disord 2008, 107:127-133.
94. Hollander E., Soorya L., Wasserman S., Esposito K., Chaplin W., Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. Int J Neuropsychopharmacol 2006, 9:209-213.
95. Otte C., Wiedemann K., Yassouridis A., Kellner M. Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study. J Clin Psychopharmacol 2007, 24:106-108.
96. Pallanti S., Quercioli L., Sood E., Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002, 63:559-564.
97. Myrick H., Brady K.T. The use of divalproex in the treatment of addictive disorders. Psychopharmacol Bull 2003, 37(Suppl. 2):89-97.
98. McElroy S.L., Keck P.E., Lawrence J.M. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci 1991, 3:232-233.
99. Rickels K., Schweizer E., Garcia Espana F., Case G., DeMartinis N., Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl) 1999, 141:1-5.
100. Basan A., Kissling W., Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res 2004, 70:33-37.
101. Casey D.E., Daniel D.G., Tamminga C., et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009, 35:1330-1338.
102. Citrome L., Shope C.B., Nolan K.A., Czobor P., Volavka J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol 2007, 22:356-362.
103. Suzuki T., Uchida H., Takeuchi H., et al. Augmentation of atypical antipsychotics with valproic acid: an open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol 2009, 24:628-638.
104. Fisk G.G., York S.M. The effect of sodium valproate on tardive dyskinesia-revisited. Br J Psychiatry 1987, 150:542-546.
105. Hellewell J.S. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002, 72:S23-S34.
106. Misdrahi D., Tournier M., Droulout T., et al. Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma levels. Eur Psychiatry 2008, 23:409-412.
107. Wagner K.D., Kowatch R.A., Emslie G.J., et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar patients in children and adolescents. Am J Psychiatry 2006, 163:1179-1186.
108. Vieta E., Cruz N., Garcia-Campayo J., et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008, 11:445-452.
109. Juruena M.F., Ottoni G.L., Machado-Vieira R., et al. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:94-99.
110. Mattes J.A. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005, 25:575-579.
111. Schik G., Wedegaertner F.R., Liersch J., Hoy L., Emrich H.M., Schneider U. Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol 2005, 10:283-288.
112. Koethe D., Juelicher A., Nolden B.M., et al. Oxcarbazepine-efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, controlled multicenter pilot study. Alcohol Clin Exp Res 2007, 31:1188-1194.
113. Martinotti G., Di Nicola M., Romanelli R., et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol 2007, 22:149-156.
114. Croissant B., Grosshans M., Diehl A., Mann K. Oxcarbazepine in rapid benzodiazepine detoxification. Am J Drug Alcohol Abuse 2008, 34:534-540.
115. Llacer J.J., Aguilella A.C. Efficacy of oxcarbazepine treatment in patients diagnosed with cocaine abuse/dependence. Adicciones 2008, 20:263-270.
116. Leweke F.M., Gerth C.W., Koethe D., Faulhaber J., Klosterkotter J. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry 2004, 161:1130-1131.
117. Kapetanovic S. Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors. Am J Psychiatry 2007, 164:832-833.
118. Beran R.G., Gibson R.J. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998, 39:280-282.
119. Cardenas J.F., Rho J.M., Ng Y.T. Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy. J Child Neurol 2010, 25:182-187.
120. Brandt C., Fueratsch N., Boehme V., et al. Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature. Epilepsy Behav 2007, 11:133-139.
121. Chistyakova Y., Amos J. Delirium associated with lamotrigine and fluoxetine treatment. Am J Psychiatry 2008, 165:918-919.
122. Kaufman K.R., Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998, 7:163-165.
123. Calabrese J.R., Hoffman R.F., White R.L., et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008, 10:323-333.
124. Geddes J.R., Calabrese J.R., Goodwin G.H. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry 2009, 194:4-9.
125. Van der Loos M.L., Mulder P.G., Hartong E.G., et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:223-231.
126. Ghaemi S.N., Shirzadi A.A., Filkowski M. Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder. Medscape J Med 2008, 10:211.
127. Belsito K.M., Law P.A., Kirk K.S., Landa R.J., Zimmerman A.W. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2008, 31:175-181.
128. Kaufman K.R. Anticonvulsants in sports: ethical considerations. Epilepsy Behav 2007, 10:268-271.
129. Santos M.A., Rocha F.L., Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, double-blind study. Prim Care Companion J Clin Psychiatry 2008, 10:187-190.
130. Tilhonen J., Wahlbeck K., Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009, 109:10-14.
131. Goff D.C., Keefe R., Citrome L., et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007, 27:582-589.
132. Poyurovsky M., Glick I., Koran L. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol 2010, 24:861-866.
133. Uzun O. Lamotrigine as an augmenting agent in treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacol 2010, 24:425-427.
134. Krupitsky E.M., Rudenko A.A., Burakov A.M., et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 2007, 31:604-611.
135. Rosen M.I., Pearsall H.R., Kosten T.R. The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug Alcohol Depend 1998, 52:173-176.
136. Brown E.S., Perantie D.C., Dhanani N., Beard L., Orsulak P., Rush A.J. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disorder 2006, 93:219-222.
137. Reich D.B., Zanarini M.C., Bieri K.A. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol 2009, 24:270-275.
138. Labiner D.M., Ettinger A.B., Fakhoury T.A., et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009, 50:434-442.
139. Devarajan S., Dursun S.M. Aggression in dementia with lamotrigine treatment. Am J Psychiatry 2000, 157:1178.
140. Ng B., Camacho A., Bardwell W., Sewell D.D. Lamotrigine for agitation in older patients with dementia. Int Psychogeriatr 2009, 21:207-208.
141. Kanner A.M., Weisbrot D.M. Psychiatric evaluation of the adult and pediatric patient with epilepsy: a practical approach for the "nonpsychiatrist.". Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment 2007, 119-132. Lippincott Williams & Wilkins, Philadelphia. 2nd ed. A.B. Ettinger, A.M. Kanner (Eds.).
142. Sharma A., Drake J., Qasimyar M., Tucker S. Improvement in depressive symptoms with felbamate: a case report. Prim Care Companion J Clin Psychiatry 2008, 10:252.
143. Zwanzger P., Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 2005, 30:167-175.
144. Macleod A.D. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996, 16:190-191.
145. Brodie J.D., Figueroa E., Dewey S.L. Treating cocaine addiction from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003, 50:261-265.
146. Brodie J.D., Case B.G., Figueroa E., et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009, 166:1269-1277.
147. Brodie J.D., Figueroa E., Laska E.M., Dewey S.L. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005, 55:122-125.
148. Korsgaard S., Casey D.E., Gerlach J. Effect of gamma-vinyl GABA in tardive dyskinesia. Psychiatry Res 1983, 8:261-269.
149. Kruszewski S.P., Paczynski R.P., Kahn D.A. Gabapentin-induced delirium and dependence. J Psychiatr Pract 2009, 15:314-319.
150. Hellwig T.R., Hammerquist R., Termaat J. Withdrawal symptoms after gabapentin discontinuation. Am J Health Syst Pharm 2010, 67:910-912.
151. Lopez P.R., Rachael T., Leicht S., Smalligan R.D. Gabapentin-induced delusions of parasitosis. South Med J 2010, 103:711-712.
152. Pande A.C., Davidson J.R., Jefferson J.W., et al. Treatment of social anxiety with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999, 19:341-348.
153. Kaufman K.R. Monotherapy treatment of paruresis with gabapentin. Int Clin Psychopharmacol 2005, 20:53-55.
154. Onder E., Tural U., Gokbakan M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?. Eur Arch Clin Neurosci 2008, 258:319-323.
155. Pande A.C., Crockatt J.G., Janney C.A., Werth J.L., Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Dis 2000, 2(3, Pt. 2):249-255. for the Gabapentin Bipolar Disorder Study Group.
156. Brower K.J., Myra K.H., Strobbe S., Karam-Hage M.A., Consens F., Zucker R.A. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008, 32:1429-1438.
157. Fuieri F.A., Nakamura-Palacios E.M. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007, 68:1691-1700.
158. Bonnet U., Hamzavi-Abedi R., Specka M., Wiltfang J., Lieb B., Scherbaum N. An open label trial of gabapentin in acute alcohol withdrawal using an oral loading protocol. Alcohol Alcohol 2010, 45:143-145.
159. Miller L.J. Gabapentin for treatment of behavioral and psychological symptoms of dementia. Ann Pharmacother 2001, 35:427-431.
160. Moretti R., Torre P., Antonello R.M., Cazzato G., Bava A. Gabapentin for the treatment of behavioral alterations in dementia: preliminary 18-month investigation. Drugs Aging 2003, 20:1035-1040.
161. Hermann N., Lanctot K., Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000, 20:90-93.
162. Hardoy M.C., Carta M.G., Carpiniello B., et al. Gabapentin in anti-psychotic-induced tardive dyskinesia: results of 1-year follow-up. J Affect Disord 2003, 125-130.
163. Gupta S., Frank B.L., Masand P.S. Gabapentin in the treatment of aggression associated with conduct disorder. Prim Care Companion J Clin Psychiatry 2000, 2:60-61.
164. Malek-Ahmadi P. Gabapentin and posttraumatic stress disorder. Ann Pharma-cother 2003, 37:664-666.
165. Hamner M.B., Brodrick P.S., Labbate L.A. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001, 13:141-146.
166. Gonzalez G., Desai R., Sofuoglu M., et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone treated patients. Drug Alcohol Depend 2007, 87:1-9.
167. Hart C.L., Haney M., Collins E.D., Rubin E., Foltin R.W. Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses. Drug Alcohol Depend 2007, 86:274-277.
168. Martinez-Raga J., Sabater A., Perez-Galvez B., Castellano M., Cervera G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:599-601.
169. Kheirabadi G.R., Ranjkeksh M., Maracy M.R., Saleshi M. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction 2008, 103:1495-1499.
170. Heinzerling K.G., Shoptaw S., Peck J.A., et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006, 85:177-184.
171. Gabriel A. Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study. Neuropsychiatr Dis Treat 2010, 6:711-717.
172. Chengappa K.N., Gershon S., Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001, 3:215-232.
173. Kushner S.F., Khan A., Lane R., Olson W.H. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo controlled trials. Bipolar Disord 2006, 8:15-27.
174. Chengappa K.N., Kupfer D.J., Parepally H., et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord 2007, 9:609-617.
175. McElroy S.L., Hudson J.I., Capece J.A., Beyers K., Fisher A.C., Rosenthal N.R. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled trial. Biol Psychiatry 2007, 61:1039-1048.
176. McElroy S.L., Frye M.A., Altshuler L.L., et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorder. Bipolar Disord 2007, 9:426-434.
177. Cates M.E., Feldman J.M., Boggs A.A., Woolley T.W., Whaley N.P. Efficacy of add-on topiramate therapy in psychiatric patients with weight gain. Ann Pharmacother 2008, 42:505-510.
178. Johnson B.A., Rosenthal N., Capece J.A., et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298:1641-1651.
179. Florez G., Saiz P.A., Garcia-Portilla P., Alvarez S., Nogueiras L., Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res 2011, 17:29-36.
180. Kampman K.M., Pettinati H., Lynch K.G., et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004, 75:233-240.
181. Cheseaux M., Monnat M., Zullino D.F. Topiramate in benzodiazepine withdrawal. Hum Psychopharmacol 2003, 18:375-377.
182. Michopoulos I., Douzenis A., Christodoulou C., Lykouras L. Topiramate use in alprazolam addiction. World J Biol Psychiatry 2006, 7:265-267.
183. Berlant J.L. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004, 4:24.
184. Lindley S.E., Carlson E.B., Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007, 27:677-681.
185. Tucker P., Trautman R.P., Wyatt D.B., et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68:201-206.
186. Dannon P.N., Lowengrub K., Gonopolski Y., Musin E., Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005, 28:6-10.
187. Loew T.H., Nickel M.K., Muehlbacher M., et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006, 26:61-66.
188. Berlin H.A., Koran L.M., Jenike M.A., et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2010 August 10, [Electronic publication ahead of print].
189. Mowla A., Pani A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol 2010, 30:40-43.
190. Fhager B., Meiri I.M., Sjogren M., Edman A. Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study. Int Psychogeriatr 2003, 15:307-309.
191. Kuo S.H., Jimenez-Shahed J. Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010, 33:32-34.
192. Jankovic J., Jimenez-Shahed J., Brown L.W. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010, 81:70-73.
193. Lochner C., Seedat S., Niehaus D.J., Stein D.J. Topiramate in the treatment of trichotillomania: an open-label pilot study. Int Clin Psychopharmacol 2006, 21:255-259.
194. White J.R., Walczak T.S., Leppik I.E., et al. Discontinuation of levetiracetam because of behavioral side effects. Neurology 2003, 61:1218-1221.
195. Dinkelacker V., Dieti T., Widman G., Lengler U., Elger C.E. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003, 4:537-547.
196. Grunze H., Langosch J., Born C., Schaub G., Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003, 64:781-784.
197. Saricicek A., Maloney K., Muralidharan A., et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010 October 19, [Electronic publication ahead of print].
198. Post R.M., Altshuler L.L., Frye M.A., et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005, 66:370-374.
199. Rugino T.A., Samsock T.C. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr 2002, 23:225-230.
200. Wasserman S., Iyengar R., Chaplin W.F., et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006, 21:363-367.
201. Papp L.A. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry 2006, 67:1573-1576.
202. Mattes J.A. Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69:310-315.
203. Sarid-Segal O., Plechniczek-Buczek J., Knapp C., et al. The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. Am J Drug Alcohol Abuse 2008, 34:441-447.
204. Richter C., Hinzpeter A., Schmidt F., et al. Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. J Clin Psychopharmacol 2010, 30:720-725.
205. Kyomen H.H., Whitfield T.H., Baldessarini R.J. Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type. J Clin Psychopharmacol 2007, 27:408-410.
206. Konitsiotis S., Pappa S., Mantas C., Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord 2006, 21:1219-1221.
207. Zivkovic S.A., Costa G., Bond G., Abu-Elmagd K.M. Treatment of tardive dyskinesia with levetiracetam in a transplant patient. Acta Neurol Scand 2008, 117:351-353.
208. Woods S.W., Saksa J.R., Baker C.B., Cohen S.J., Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008, 69:546-554.
209. Oulis P., Karapoulios E., Masdrakis V.G., et al. Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome. World J Biol Psychiatry 2008, 9:76-77.
210. Fernandez-Jaen A., Fernandez-Mayoralas D.M., Munoz-Jareno N., Calleja-Perez B. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 2009, 13:541-545.
211. Smith-Hicks C.L., Bridges D.D., Paynter N.P., Singer H.S. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764-1770.
212. Hedderick E.F., Morris C.M., Singer H.S. Double-blind, crossover study of clonidine and levetiracetam in Tourette's syndrome. Pediatr Neurol 2009, 40:420-425.
213. Kayatekin Z.E., Sabo A.N., Halbreich U. Levetiracetam for treatment of premenstrual dysphoric disorder: a pilot, open-label study. Arch Womens Ment Health 2008, 11:207-211.
214. McElroy S.L., Suppes T., Keck P.E., et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 2005, 66:617-624.
215. Ghaemi S.N., Zablotsky B., Filkowski M.M., et al. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 2006, 26:385-388.
216. Kinrys G., Vasconcelos e Sa D., Nery F. Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 2007, 61:1050-1053.
217. McElroy S.L., Kotwal R., Guerdjikova A.I., et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006, 67:1897-1906.
218. Wang P.W., Yang Y.S., Chandler R.A., et al. Adjunctive zonisamide for weight loss in euthymic bipolar patients: a pilot study. J Psychiatr Res 2008, 42:451-457.
219. Knapp C.M., Sarid-Segal O., Richardson M.A., et al. Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Abuse 2010, 36:102-105.
220. Rubio G., Lopez-Munoz F., Ferre F., et al. Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol 2010, 33:250-253.
221. Arias A.J., Feinn R., Oncken C., Covault J., Kranzler H.R. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 2010, 30:318-322.
222. Flowers C.M., Racoosin J.A., Kortepeter C. Seizure activity and off-label use of tiagabine. N Engl J Med 2006, 354:773-774.
223. Mula M., Sander J.W. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007, 30:555-567.
224. Kaufman K.R. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998, 10:181-184.
225. Schaffer L.C., Schaffer C.B., Howe J. An open case series on the utility of tiagabine as an augmentation in refractory bipolar disorder. J Affect Disord 2002, 7:259-263.
226. Suppes T., Chisholm K.A., Dhavale D., et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002, 4:283-289.
227. Grunze H., Erfurth A., Marcuse A., Amann B., Normann C., Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999, 60:759-762.
228. Oulis P., Masdrakis V.G., Karapoulios E., et al. Tiagabine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder. World J Biol Psychiatry 2009, 10(4, Pt. 3):953-955.
229. Davidson J.R., Brady K., Mellman T.A., Stein M.B., Pollack M.H. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007, 27:85-88.
230. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003, 64:1245-1249.
231. Pollack M.H., Tiller J., Xie F., Trivedi M.H. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008, 28:308-316.
232. Zwanzger P., Eser D., Nothdurfter C., et al. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry 2009, 42:266-269.
233. Dunlop B.W., Papp L., Garlow S.J., Weiss P.S., Knight B.T., Ninan P.T. Tiagabine for social anxiety disorder. Hum Psychopharmacol 2007, 22:241-244.
234. Hoffman D.A. Tiagabine for rage, aggression, and anxiety. J Neuropsychiatry Clin Neurosci 2005, 17:252.
235. Paparrigopoulos T., Tzavellas E., Karaiskos D., Malitas P., Liappas I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J Psychopharmacol 2010, 24:1375-1380.
236. Myrick H., Taylor B., LaRowe S., et al. A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal. J Psychoactive Drugs 2005, 37:409-414.
237. Winhusen T, Somoza E, Ciraulo DA, et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drugs Alcohol Depend 2007;91:141-8.
238. Oulis P., Masdrakis V.G., Karapoulios E., Karakatsanis N.A., Kouzoupis A.V., Papadimitriou G.N. Tiagabine in the discontinuation of long-term benzodiazepine use. Psychiatry Clin Neurosci 2009, 63:122.
239. Hindmarch I., Trick L., Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 2005, 183:133-143.
240. Salinsky M., Storzbach D., Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 2010, 75:755-761.
241. Grosshans M., Mutschler J., Hermann D., et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010, 167:869.
242. Kasper S., Herman B., Nivoli G., et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009, 24:87-96.
243. Oulis P., Florakis A.A., Tzanoulinos, Papadimitriou G.N. Adjunctive pregabalin to quetiapine in acute mania. Clin Neuropharmacol 2009, 32:174.
244. Showraki M. Pregabalin in the treatment of depression. J Psychopharmacol 2007, 21:883-884.
245. Pande A.C., Feltner D.E., Jefferson J.W., et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004, 23:141-149.
246. Pae C.U., Marks D.M., Han C., Masand P.S., Patkar A.A. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol 2009, 24:29-33.
247. Di Nicola M., Martinotti G., Tedeschi D., et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol Clin Exp 2010, 25:268-275.
248. Martinotti G., Di Nicola M., Romanelli R., et al. Pregabalin, tiapride, and lorazepam in alcohol withdrawal syndrome; a multi-centre, randomized, single-blind comparison trial. Addiction 2010, 105:288-299.
249. Martinotti G., Di Nicola M., Tedeschi D., et al. Pregabalin versus naltrexone in alcohol dependence: a randomized, double-blind, comparator trial. J Psychopharmacol 2010, 24:1367-1374.
250. Oulis P., Konstantakopoulos G., Kouzoupis A.V., et al. Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum Psychopharmacol 2008, 23:337-340.
251. Englisch S., Esser A., Ennning F., Hohmann S., Schanz H., Zink M. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010, 30:437-440.
252. Harnack D., Schmeel M., Mundt A., Heinz A., Strohle A. Pregabalin in patients with antidepressant treatment-resistant somatoform disorders: a case series. J Clin Psychopharmacol 2007, 27:537-539.
253. Higgins G.A., Breysse N., Undzys E., et al. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. Psychopharmacology (Berl) 2010, 207:513-527.
254. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009, 5:757-766.
255. Wehner T., Bauer S., Hamer H.M., et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary center in Germany. Epilepsy Behav 2009, 16:423-425.
256. Higgins G.A., Breysse N., Undzys E., et al. The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents. Eur J Pharmacol 2009, 624:1-9.
257. Brodie M.J., Rosenfeld W.E., Vazquez B., et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
258. Kluger G., Glauser T., Krauss G., Seeruthun R., Perdomo C., Arroyo S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010, 122:202-208.
259. Kluger G., Kurlemann G., Haberlandt E., et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009, 14:491-495.
260. Fava M. The possible antianxiety and mood-stabilizing effects of rufinamide. Psychother Psychosom 2010, 79:194-195.
261. Chung S.S. Third generation antiepileptic drugs for partial-onset seizures: lacosamide, retigabine, and eslicarbazepine acetate. Eur J Neurol 2009, 1:1-11.
262. Milovan D., Almeida L., Romach M.K., et al. Effects of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav 2010, 18:366-373.
263. Porter R.J., Partiot A., Sachdeo R., Nohria V., Alves W.M. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68:1197-1204.
264. Brodie M.J., Lerche H., Gil-Nagel A., et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010, 75:1817-1824.
265. Amann B., Sterr A., Vieta E., Stampfer R., Walden J., Grunze H. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J Clin Psychopharmacol 2006, 26:534-536.
266. Kaufman K.R. Comparative bioethics in bipolar and epilepsy research. Seizure 2002, 11:51-56.
267. Vedula S.S., Bero L., Scherer R.W., Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009, 361:1963-1971.
268. Kanner A.M. When did neurologists and psychiatrists stop talking to each other?. Epilepsy Behav 2003, 4:597-601.
269. Brady K.T. Expanding treatment options for cocaine dependence. Am J Psychiatry 2009, 166:1209-1210.
270. Kaufman K.R. Antiepileptic drugs in the treatment of psychiatric disorders. Atlas of epilepsies 2010, 1571-1576. Springer, London. C.P. Panayiotopoulos (Ed.).